What Is DSIP Studied For? Research Areas, Per the Literature

The phrase "what is DSIP used for" is answered here in one way only: as a summary of what delta sleep inducing peptide (DSIP) has been studied for in the published literature. Research questions are not the same as established uses, and an experiment in rats or mice is not a demonstration of a human outcome. DSIP is not approved by the FDA as a medicine for any condition. This page is not guidance.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, symptom or substance. No doses, routes, schedules or sourcing information appear anywhere on this page, and none should be inferred from the research descriptions below.

What DSIP Is, In Plain Terms

DSIP is a short peptide first described in sleep physiology research, which is where its name comes from. Like other short peptides, it can be prepared by chemical synthesis, and the chemistry literature continues to refine how peptide chains are assembled, including work on practical N-to-C synthesis strategies that reduce protecting group requirements (PMID 37884638). That synthesis work is general peptide chemistry and says nothing about DSIP biology; it is included only to make clear that availability of a synthetic peptide tells a reader nothing about whether its biological effects have been tested in people.

The name "delta sleep inducing peptide" is descriptive of the historical context in which the molecule was named, not a statement of proven function. None of the verified papers summarised on this page is a human sleep trial.

Research Area 1: Neuronal Activity and NMDA Receptor Signalling

One line of DSIP research has looked at how the peptide relates to the excitability of neurons when glutamate, the main excitatory neurotransmitter in the mammalian brain, is applied directly to them. A 2004 neurophysiology study examined neuronal activity after glutamate microiontophoresis and addressed the role of NMDA receptors in the response to delta sleep inducing peptide (PMID 15364118). Microiontophoresis is a laboratory technique in which tiny amounts of a substance are released next to a single recorded neuron, so the model is a preclinical electrophysiology preparation rather than a clinical population.

What this type of work can support is a mechanistic hypothesis: that DSIP activity may intersect with glutamatergic transmission and NMDA receptor function (PMID 15364118). What it cannot support is any claim about sleep quality, mood, pain or recovery in humans, because single neuron recordings do not measure those outcomes.

Research Area 2: Stress Physiology in Rodents

Cortical neuron structure and stress resistance

A 2003 morphology study described the structural and functional organisation of cerebral cortex neurons in rats characterised as having different levels of resistance to emotional stress, following administration of delta sleep inducing peptide (PMID 12891772). The model was the laboratory rat, and the outcome measures were anatomical and cytological features of cortical neurons rather than behaviour tests or clinical scales.

The design detail that matters for interpretation is the split by stress resistance: researchers compared animals that differed in how they responded to emotional stress, which is a within-rodent trait grouping and does not map onto any human diagnostic category (PMID 12891772).

Liver cell function during foot shock stress

A 2015 Russian physiology paper examined the influence of delta sleep inducing peptide on the functional state of rat hepatocytes during foot shock stress (PMID 26470489). The population was rats exposed to an experimental stressor, and the measured system was the liver, specifically the functional state of hepatocytes, which is a tissue level readout.

Taken together, these two animal papers define a research area rather than an application: whether DSIP interacts with the physiological consequences of experimental stress in rodent brain and liver tissue (PMID 12891772, PMID 26470489). Neither study enrolled humans, and neither measured subjective stress, anxiety or sleep as a person would experience them.

Research Area 3: Ageing, Longevity and Carcinogenesis in Mice

A 2009 gerontology paper reported on a DSIP preparation known as Deltaran and its effect on longevity, physiological functions and carcinogenesis in mice (PMID 20405733). The model was the laboratory mouse followed over the lifespan, and the endpoints named in the study were survival related, functional and tumour related.

Lifespan studies in mice are a recognised preclinical approach in ageing research, but they are also among the hardest results to translate, because mouse strain, housing, diet and tumour background strongly shape outcomes. The appropriate reading of this work is that longevity and carcinogenesis endpoints were studied in mice given a DSIP preparation (PMID 20405733), not that any anti-ageing or anti-cancer effect has been established in people.

Summary Table of Research Areas in This Citation Set

Searched-For Uses Where The Evidence Here Is Weak Or Absent

Plain statements matter more than hedging when evidence is missing. Within the verified literature summarised on this page, there is no human clinical trial of DSIP for any indication. That means the following commonly searched topics are not supported by the papers cited here:

• Insomnia and sleep architecture in humans. Despite the peptide's name, no human sleep trial appears in this citation set; the closest mechanistic work is rodent neurophysiology on glutamate responses and NMDA receptors (PMID 15364118).
• Anxiety, depression or mood disorders. The rat work described cortical neuron organisation in animals differing in stress resistance, which is a tissue level observation and not a psychiatric outcome (PMID 12891772).
• Chronic pain, fibromyalgia or headache. No pain study appears among the verified papers; absence of a citation here means absence of supporting evidence on this page, not hidden support elsewhere.
• Alcohol or opioid withdrawal. No withdrawal study appears in this citation set.
• Athletic recovery, body composition or performance. No such study appears in this citation set.
• Cancer prevention or treatment in humans. Carcinogenesis was an endpoint in a mouse lifespan study only (PMID 20405733), which does not establish any human result.

Readers encountering confident claims about these topics elsewhere can apply a simple test: ask which study, in which species, with which measured outcome, and whether a PubMed identifier accompanies the claim.

Safety and Adverse Events: What Studies Report

The verified papers summarised here are animal and laboratory studies, and none of them is a human safety trial, so no human adverse event profile for DSIP can be described from this citation set. The mouse study that followed animals across the lifespan assessed longevity, physiological functions and carcinogenesis as endpoints (PMID 20405733), and endpoints of that kind are the usual place where long term harm signals would appear in rodent ageing research, though a rodent result does not predict human tolerability.

The rat studies measured tissue level outcomes, specifically cortical neuron organisation (PMID 12891772) and hepatocyte functional state under stress (PMID 26470489), rather than clinical safety signs such as blood pressure, laboratory panels or symptom reporting in people. Because this page states no doses, readers should note that no dose related safety statement is being made in either direction.

How To Read Preclinical DSIP Evidence

1. Check the species. Every biological finding cited on this page came from rats, mice or isolated neuronal recordings (PMID 15364118, PMID 20405733).
2. Check the outcome measured. Hepatocyte functional state is a laboratory measurement, not a clinical symptom (PMID 26470489).
3. Check the stressor or challenge. Foot shock and experimental emotional stress models are standardised laboratory challenges, not analogues of daily human stress (PMID 26470489, PMID 12891772).
4. Check whether replication exists. Several of the DSIP papers here are single studies in specialised journals, and single preclinical studies are the weakest rung of the evidence ladder.
5. Separate chemistry from biology. Advances in how peptides are synthesised (PMID 37884638) say nothing about whether a peptide works in a living organism.

Regulatory Context

Regulatory status is a separate question from research interest. A compound can appear in decades of laboratory literature and still have no approved medical product behind it. DSIP is not approved by the FDA as a medicine for any condition. This page is not guidance. Materials labelled for research use only are intended for laboratory work and are not medicines, and nothing on this page describes acquisition, preparation or administration.

Bottom Line

Asked as a research question, "what is DSIP used for" has a narrow answer in the verified literature: it has been used as an experimental probe in rodent and neurophysiology studies covering glutamate and NMDA receptor related neuronal activity (PMID 15364118), stress related changes in cortical neurons (PMID 12891772) and liver cells (PMID 26470489), and lifespan and carcinogenesis endpoints in mice (PMID 20405733). Human clinical evidence is not represented in this citation set.

Related reading: DSIP overview.

References

• Delta-sleep inducing peptide and neuronal activity after glutamate microiontophoresis: the role of NMDA-receptors (Pathophysiology, 2004)
• Structural and functional organization of the cerebral cortex neurons in rats with various resistance to emotional stress following administration of delta-sleep-inducing peptide (Morfologiia, 2003)
• The influence of delta sleep-inducing peptide on functional state of rats hepatocytes in foot-shock stress (Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2015)
• Effect of delta-sleep inducing peptide preparation Deltaran on longevity, physiological functions, and carcinogenesis in mice (Advances in Gerontology, 2009)
• Practical N-to-C peptide synthesis with minimal protecting groups (Communications Chemistry, 2023)